JPRN-UMIN000006078已完成2 期
A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer - A phase II study of Erlotinib as 2nd-line treatment for patients with StageIIIB/IV non-small cell lung cancer
Yamagata University School of Medicine0 个研究点目标入组 31 人开始时间: 2011年7月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2)Patients with active severe infections 3)Impossible cases with oral administration 4)Patients with active opthalmological disease 5)Pregnancy or lactation 6)Patients with active concomitant malignancy 7)Patients with uncontrollable diabetes mellitus 8)Patients with uncontrollable complications 9)Inappropriate patients for this study judged by the physicians
研究者
相似试验
已完成
2 期
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung canceradvanced non-small cell lung cancerJPRN-UMIN000004227Hamamatsu University School of Medicine30
已完成
不适用
Phase II study of erlotinib as first line chemotherapy in patients with lung adenocarcinoma with brain metastasis and EGFR mutations.lung adenocarcinomaJPRN-UMIN000013502Osaka city General Hospital25
进行中（未招募）
1 期
A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR - Study of targeted Erlotinib treatment for Non-small cell lung cancerStage IIIb/IV non-small cell lung cancer (NSCLC) tumours that over-express EGFRMedDRA version: 9.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIBMedDRA version: 9.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2007-001264-72-GBOxford Radcliffe Hospitals NHS Trust35
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54